How Should Clinics Evaluate a Clinical AI Pilot for Care Coordination in 2026?

What Is a Clinical AI Pilot Evaluation?

A clinical AI pilot evaluation is a structured, time-limited test of whether an AI-supported workflow improves care coordination, patient access, clinician workload, or operational performance without creating unacceptable safety, equity, privacy, or financial risks. It is not simply a demonstration of an algorithm, a software trial, or a count of automated messages sent. For clinics and care networks, the central question is whether the technology works reliably inside real operations, with real patients, clinicians, data systems, and exceptions.

Also worth reading: How does patient pulse coordination software improve emergency medication access in clinics? · How Can HIPAA Scheduling for Care Networks Power Secure B2B Care Coordination? · How Do You Choose the Right Care Coordination Software Vendors in 2026?

A credible evaluation begins with a narrow use case, such as identifying patients at risk of missed follow-up, preparing referral information, summarizing care-plan activity, or monitoring patient-reported symptoms between visits. The baseline should be established before deployment, and results should be reviewed at predefined intervals. As of 26 September 2026, evaluation should also account for growing regulatory attention to AI in healthcare, including the FDA’s reported completion of an AI-assisted scientific review pilot and its broader institutional use of AI. Regulatory activity does not automatically make a care-coordination product approved or clinically validated; it raises the standard for documentation, oversight, and evidence.

The best pilot is measurable, reversible, and owned by a multidisciplinary team. It should test the system in a defined population rather than making an enterprise-wide purchasing decision after a short demo. The output should include evidence of benefit, evidence of failure modes, and a decision about whether to expand, revise, pause, or stop. A pilot that cannot answer those questions may still be useful for discovery, but it should not be described as proof of clinical effectiveness.

How to Design a Useful Clinical AI Pilot

Start by selecting one workflow with a clear owner and a measurable decision. For example, a care-coordination team might test AI-generated outreach lists for patients with overdue chronic-disease follow-up, while a separate pilot might examine AI preparation of discharge information. Avoid combining unrelated objectives such as triage, documentation, scheduling, risk prediction, and patient messaging in one evaluation. Each objective has different data requirements, failure consequences, and success criteria.

Define the patient population, intervention period, comparison period, and exclusions before examining results. A practical minimum is a four- to eight-week operational pilot, followed by several weeks of analysis, with longer observation when outcomes involve appointments, referrals, admissions, or disease control. A three-month baseline may be appropriate for seasonal conditions, while a 12-month view is more useful for annual utilization and total-cost measures. The evaluation should include staff time, patient contacts, completion of care actions, false positives, missed cases, escalations, and user-reported burden.

Use a control design where feasible: matched clinics, staggered rollout, historical comparison, or randomized assignment at the team or patient level. A before-and-after comparison alone can be misleading if staffing, referral volume, coding, or patient mix changed during the pilot. Record the exact AI version, prompt or configuration, data sources, integration method, and any human review rules. Without that information, a favorable result may reflect workflow redesign rather than the AI itself.

Metrics That Matter for Care Coordination

Metrics should connect technical performance to patient and operational outcomes. Model-level measures such as sensitivity, specificity, precision, calibration, and drift are necessary, but they do not replace measures of whether patients received appropriate care. A system with 95% accuracy can still be operationally poor if it produces too many false alarms, requires excessive manual review, or acts on stale information.

For a care-coordination pilot, divide measures into four groups. First, process measures include the number of eligible patients identified, outreach attempted, referrals completed, follow-up appointments booked, and care plans updated. Second, outcome measures might include completed screenings, reduced time to specialist review, fewer missed transitions, improved chronic-disease control, or reduced avoidable utilization. Third, safety measures include inappropriate outreach, duplicate interventions, missed high-risk cases, privacy incidents, and clinician overrides. Fourth, experience measures include staff time per case, patient comprehension, response rate, and trust or satisfaction.

Set thresholds in advance. Examples include at least 90% successful synchronization with the source system, fewer than 5% critical cases requiring immediate human escalation, a 20% reduction in administrative time, or at least 10% improvement in referral completion. These are planning examples, not universal standards. A clinic should adjust thresholds according to clinical risk, population size, baseline performance, and the cost of failure. For a high-risk prediction use case, even a 1% miss rate may be unacceptable; for a low-risk administrative task, the threshold may be more permissive if human review is mandatory.

Safety evaluation must include what happens when the system is uncertain or wrong. Document missing data, contradictory patient information, outdated records, duplicate records, inaccessible language, and mismatches between the AI recommendation and the care plan. Every alert should have a clear disposition: accepted, rejected, deferred, escalated, or investigated. Counting only accepted recommendations hides the operational burden and cannot reveal systematic failure.

Equity analysis should compare performance across relevant groups, including language, age, disability status, race or ethnicity where legally and ethically appropriate, insurance type, geography, and digital access. Do not assume that an overall sensitivity score protects every subgroup. A lower response rate among patients with limited connectivity, for example, may reflect access barriers rather than the algorithm itself, but the resulting operational inequality still matters. Review whether outreach is burdensome, whether patients can opt out, and whether staff have enough time to respond appropriately.

Data quality should be audited before and during the pilot. Measure completeness, timeliness, coding consistency, identity matching, provenance, and the proportion of records that are clinically current. The system should also be tested against changed workflows, such as a new EHR, revised referral policy, or different staffing model. The FDA’s reported work on real-time review and institutional AI use reinforces a broader regulatory direction toward traceability and oversight, while clinical teams must still verify the actual performance of the product they deploy.

How to Compare AI Alternatives and Human Workflows

A clinical AI pilot should compare the proposed system with credible alternatives, not only with the status quo. A manual registry may be cheaper for a small clinic, while rules-based automation may be more predictable for a narrow task. Existing EHR features, centralized care-management teams, staffing changes, and improved scheduling processes can sometimes produce similar gains without adding another vendor. A good evaluation asks whether AI provides enough additional value to justify its complexity.

Compare the AI option with at least one conventional workflow and, where appropriate, with a simplified rules-based approach. For example, test whether AI prioritization finds more overdue follow-up than a registry using simple date rules, while tracking false positives and staff workload. If both approaches produce comparable results, the simpler option may be preferable. If AI improves sensitivity or saves substantial staff time, quantify those gains after accounting for integration, training, supervision, and ongoing monitoring.

Purchasing evaluation should include total cost of ownership. A low subscription price does not mean a low-cost program if implementation requires interface work, data cleanup, security review, clinical governance, training, and monthly review. Ask whether pricing is per provider, per site, per patient, per message, per case, or per enterprise. Clarify whether usage is capped, whether emergency support is included, and what fees apply for additional modules or environments. Contracts should state who owns pilot data, how long data is retained, whether the vendor may use de-identified data for product improvement, and how the clinic can export its data if the relationship ends.

Common Mistakes in Clinical AI Pilots

One common mistake is treating a technically impressive demonstration as a clinical evaluation. A model may perform well on a curated dataset but fail when records are incomplete, users enter information differently, or the population differs from the training population. Another mistake is selecting only satisfaction surveys or message-response rates, which can show activity without showing better care. The pilot should include outcomes and harms as well as positive signals.

Second, teams often fail to define a baseline. If no pre-pilot data exists, it becomes difficult to determine whether improvement came from the AI. Third, many pilots expand too early, before rare safety events or subgroup differences appear. Fourth, vendors may report only aggregate performance, hiding the cases in which clinicians had to correct the system. Fifth, staff may receive inadequate training, turning a product problem into a resistance problem.

Sixth, human oversight can be nominal rather than real. If clinicians must review every output but have only seconds to do so, the workflow may create more risk than value. Seventh, equity is sometimes treated as a later compliance exercise. It should be part of the first measurement plan. Finally, pilot teams sometimes ignore model drift. A system that works during one month may degrade after a new EHR release, a change in referral patterns, or a shift in patient behavior. Version control and periodic revalidation are necessary for any continuing deployment.

When to Expand, Revise, or Stop the Pilot

Expand only when the product meets predefined clinical, operational, safety, and financial criteria. Expansion should be staged, such as from 2 clinics to 10 and then to a larger network, with a checkpoint between stages. The same success thresholds should apply at every stage unless the risk profile changes. Expansion should not be based solely on a positive vendor case study, a successful executive demonstration, or early adoption by enthusiastic staff.

Revise the pilot when performance is promising but inconsistent. Common reasons include poor data integration, unclear escalation rules, excessive false positives, low user trust, or a mismatch between the intended population and actual patients. A revised pilot should change one or two design elements at a time so the team can understand what worked. For instance, it might narrow the use case, add clinician confirmation, improve the registry, or change the outreach channel.

Stop when the tool cannot meet safety requirements, produces no measurable benefit after a fair test, creates unsustainable workload, or cannot be integrated securely. Stopping is not necessarily a failure; it is a valid governance outcome and can prevent waste. Document the reasons, preserve the evidence, and communicate them to leadership and frontline staff. A vendor that resists external evaluation, refuses to provide performance by subgroup, or pressures the clinic into a rapid rollout should be treated as a warning sign.

A Practical Budget and Decision Framework

Costs vary widely because the product, integration burden, clinical scope, and staffing model differ. As a planning range for a small clinic or care network, a narrow workflow pilot may require approximately $10,000 to $50,000 for setup, integration, security review, training, and evaluation. A multi-site deployment involving multiple EHR environments, custom data work, clinical measurement, and vendor licensing can reach $50,000 to $250,000 or more. These figures are budgeting estimates, not quoted market prices.

The return calculation should include avoided staff hours, reduced rework, increased completed referrals, improved appointment throughput, and possibly lower avoidable utilization. It should also include licensing, interface maintenance, data governance, monitoring, patient support, and the cost of correcting errors. A tool that saves 30 minutes per case but requires 20 minutes of review may deliver little net capacity. Measure actual staff time rather than assuming that automation automatically becomes savings.

A decision memo should state the use case, baseline, target thresholds, sample size, pilot duration, safety controls, results, limitations, total cost, and recommended next action. It should distinguish evidence from inference. For example, “the system reduced review time by 18% in two clinics” is a measured result; “the system will reduce readmissions across the network” is an unproven projection. Leadership should approve the next stage only when the evidence matches the intended scale.

The strongest 2026 clinical AI pilot is therefore modest, measurable, and accountable. It tests one workflow, compares against a real alternative, includes human oversight, examines subgroup performance, and produces a clear expand-revise-stop decision. This approach allows a clinic to learn without confusing novelty with benefit and to build the operational discipline required for responsible AI-supported care coordination.